Expected

Like
Comment
Favorite

小虎8888
2022-08-09

Expected

Novavax Sinks After Halving Sales Forecast on Low Vaccine Demand, Supply Glut

Aug 8 (Reuters) - Novavax Inc on Monday halved its full-year revenue forecast as it does not expect

Novavax Sinks After Halving Sales Forecast on Low Vaccine Demand, Supply Glut

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

Top
Latest

No comments yet

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":9904310522,"tweetId":"9904310522","gmtCreate":1660001957669,"gmtModify":1703476689677,"author":{"id":3562199999723520,"authorId":3562199999723520,"authorIdStr":"3562199999723520","name":"小虎8888","avatar":"https://static.tigerbbs.com/4b891a0a5cf56a8b9b4ece04c5d71991","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":7,"crmLevelSwitch":1,"individualDisplayBadges":[],"fanSize":7,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Expected&nbsp;</p></body></html>","htmlText":"<html><head></head><body><p>Expected&nbsp;</p></body></html>","text":"Expected","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/9904310522","repostId":1127868240,"repostType":2,"repost":{"id":"1127868240","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1659998462,"share":"https://www.laohu8.com/m/news/1127868240?lang=&edition=full","pubTime":"2022-08-09 06:41","market":"us","language":"en","title":"Novavax Sinks After Halving Sales Forecast on Low Vaccine Demand, Supply Glut","url":"https://stock-news.laohu8.com/highlight/detail?id=1127868240","media":"Reuters","summary":"Aug 8 (Reuters) - Novavax Inc on Monday halved its full-year revenue forecast as it does not expect ","content":"<html><head></head><body><p>Aug 8 (Reuters) - Novavax Inc on Monday halved its full-year revenue forecast as it does not expect further sales of its COVID-19 shot this year in the United States in the face of a global supply glut, sending its shares down 32%.</p><p><img src=\"https://static.tigerbbs.com/8e213caec3d81f6142e05fd083db3b85\" tg-width=\"830\" tg-height=\"624\" width=\"100%\" height=\"auto\"/></p><p>Novavax said it now expects 2022 total revenue in the range of $2 billion to $2.3 billion, compared with its prior forecast of $4 billion to $5 billion.</p><p>The dismal outlook is the latest setback for Novavax that has also faced manufacturing hurdles and regulatory delays amid competition with market leaders Pfizer and Moderna.</p><p>Novavax&#39;s protein-based vaccine got U.S. authorization last month for use among adults and health officials had hoped the shot&#39;s more traditional technology would convince people skeptical of messenger RNA technology used by Pfizer and Moderna to get vaccinated.</p><p>However, only 7,381 doses of Novavax&#39;s vaccine have been administered in the United States so far, according to the latest government data.</p><p>The company&#39;s executives admitted on a conference call that they were late to the market in the United States and are now projecting no new revenue from the country in the year.</p><p>Novavax said it sold 3 million doses of the vaccine in the second quarter ended June 30, recording $55 million in sales. This compares to $586 million in the first quarter.</p><p>Novavax also said it does not expect to receive an order in 2022 from the COVAX facility, which is backed by the World Health Organization, the global vaccine alliance Gavi and the Coalition for Epidemic Preparedness Innovations.</p><p>Last week, Moderna maintained its full-year COVID-19 vaccine sales forecast as canceled orders from low- and middle-income nations through the COVAX program offset gains from new booster dose orders.</p><p>Moderna&#39;s shares dropped 2%, while Novavax fell 33% to $38.80 in extended trading.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Sinks After Halving Sales Forecast on Low Vaccine Demand, Supply Glut</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Sinks After Halving Sales Forecast on Low Vaccine Demand, Supply Glut\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2022-08-09 06:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Aug 8 (Reuters) - Novavax Inc on Monday halved its full-year revenue forecast as it does not expect further sales of its COVID-19 shot this year in the United States in the face of a global supply glut, sending its shares down 32%.</p><p><img src=\"https://static.tigerbbs.com/8e213caec3d81f6142e05fd083db3b85\" tg-width=\"830\" tg-height=\"624\" width=\"100%\" height=\"auto\"/></p><p>Novavax said it now expects 2022 total revenue in the range of $2 billion to $2.3 billion, compared with its prior forecast of $4 billion to $5 billion.</p><p>The dismal outlook is the latest setback for Novavax that has also faced manufacturing hurdles and regulatory delays amid competition with market leaders Pfizer and Moderna.</p><p>Novavax&#39;s protein-based vaccine got U.S. authorization last month for use among adults and health officials had hoped the shot&#39;s more traditional technology would convince people skeptical of messenger RNA technology used by Pfizer and Moderna to get vaccinated.</p><p>However, only 7,381 doses of Novavax&#39;s vaccine have been administered in the United States so far, according to the latest government data.</p><p>The company&#39;s executives admitted on a conference call that they were late to the market in the United States and are now projecting no new revenue from the country in the year.</p><p>Novavax said it sold 3 million doses of the vaccine in the second quarter ended June 30, recording $55 million in sales. This compares to $586 million in the first quarter.</p><p>Novavax also said it does not expect to receive an order in 2022 from the COVAX facility, which is backed by the World Health Organization, the global vaccine alliance Gavi and the Coalition for Epidemic Preparedness Innovations.</p><p>Last week, Moderna maintained its full-year COVID-19 vaccine sales forecast as canceled orders from low- and middle-income nations through the COVAX program offset gains from new booster dose orders.</p><p>Moderna&#39;s shares dropped 2%, while Novavax fell 33% to $38.80 in extended trading.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1127868240","content_text":"Aug 8 (Reuters) - Novavax Inc on Monday halved its full-year revenue forecast as it does not expect further sales of its COVID-19 shot this year in the United States in the face of a global supply glut, sending its shares down 32%.Novavax said it now expects 2022 total revenue in the range of $2 billion to $2.3 billion, compared with its prior forecast of $4 billion to $5 billion.The dismal outlook is the latest setback for Novavax that has also faced manufacturing hurdles and regulatory delays amid competition with market leaders Pfizer and Moderna.Novavax's protein-based vaccine got U.S. authorization last month for use among adults and health officials had hoped the shot's more traditional technology would convince people skeptical of messenger RNA technology used by Pfizer and Moderna to get vaccinated.However, only 7,381 doses of Novavax's vaccine have been administered in the United States so far, according to the latest government data.The company's executives admitted on a conference call that they were late to the market in the United States and are now projecting no new revenue from the country in the year.Novavax said it sold 3 million doses of the vaccine in the second quarter ended June 30, recording $55 million in sales. This compares to $586 million in the first quarter.Novavax also said it does not expect to receive an order in 2022 from the COVAX facility, which is backed by the World Health Organization, the global vaccine alliance Gavi and the Coalition for Epidemic Preparedness Innovations.Last week, Moderna maintained its full-year COVID-19 vaccine sales forecast as canceled orders from low- and middle-income nations through the COVAX program offset gains from new booster dose orders.Moderna's shares dropped 2%, while Novavax fell 33% to $38.80 in extended trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":202,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":8,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}